Recent News

• 11.13.2025 - Q3 2025 Earnings
• 08.14.2025 - Q2 2025 Earnings
• 05.28.2025 - Annual General Meeting 2025
• 05.08.2025 - Q1 2025 Earnings
• 03.13.2025 - March 12, 2025 9:30 PM EDT - March 12, 2025 9:55 PM EDT : Barclays 27th Annual Global Healthcare Conference Miami
• 03.07.2025 - Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
• 02.27.2025 - Q4 2024 Earnings (Full Year)
• 02.24.2025 - Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET
• 02.21.2025 - Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
• 02.18.2025 - Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Recent Filings

• 02.24.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.24.2025 - EX-99.1 EX-99.1
• 02.18.2025 - EX-99.1 EX-99.1
• 02.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.27.2025 - EX-99.1 EX-99.1
• 01.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.23.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]